BiotechTube
Vantis Vascular

Vantis Vascular

San Jose, United States· Est.
vantisvascular.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Vantis Vascular is a clinical-stage medical device innovator targeting the high-growth market for complex vascular interventions. The company's core technology is the CrossFast™ system, a dual-catheter delivery platform engineered to navigate challenging anatomies, with the potential to reduce complications and increase procedural efficiency. Founded by physicians, Vantis is leveraging its platform to develop next-generation solutions, including an intravascular lithotripsy (IVL) system and specialized peripheral (BTK) devices. With a seasoned leadership team experienced in vascular device startups and exits, the company is positioned to address significant unmet needs in interventional cardiology and vascular medicine.

CardiovascularPeripheral Artery Disease

Technology Platform

CrossFast™ Advanced Vascular Delivery System: a 'two-as-one' integrated catheter system with an auto-locking inner monorail microcatheter and an outer delivery catheter, engineered for precise control and deliverability in complex vascular anatomies.

Funding History

2
Total raised:$12M
Series A$10M
Seed$2M

Opportunities

The growing prevalence of complex, calcified coronary and peripheral artery disease cases presents a significant unmet need for specialized delivery and treatment devices.
The rapid adoption of intravascular lithotripsy (IVL) creates a timely entry point for a next-generation system integrated with a superior delivery platform.
Expansion into the challenging below-the-knee peripheral market addresses another high-need area with limited competition.

Risk Factors

Intense competition from large, established medical device companies with extensive sales forces and bundled purchasing agreements poses a major barrier to market adoption.
The company is dependent on successful regulatory clearance (FDA/CE) and the generation of compelling clinical data to demonstrate superiority over existing techniques.
As a private, likely venture-backed startup, Vantis faces execution and funding risks, requiring additional capital to complete development and achieve commercial scale.

Competitive Landscape

Vantis operates in the highly competitive vascular intervention market, competing against giants like Boston Scientific, Medtronic, Abbott, and Philips for coronary and peripheral devices. In the specific niche of complex lesion access, it faces competition from specialized microcatheter and guide extension catheter companies. In intravascular lithotripsy, it would challenge the established market leader, Shockwave Medical (acquired by Johnson & Johnson).

More companies in Digital Health & Biotech SaaS →More companies in United States →